{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:52:01Z","timestamp":1792601521031,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute myeloid leukemia (AML) is the most common type of leukemia in adults. Despite advances in treatment, the average survival rate after diagnosis is low. AML also alters the patient's immune response further contributing to disease progression. The aim of this study was to analyze the expression of LAG-3, TIM-3 and PD-1 inhibitory checkpoints on NK cells and T cells from newly diagnosed AML patients and its impact in patient survival. NK cells and T cells from AML patients showed a lower expression of TIM-3 compared with healthy donors, whereas no significant differences were observed in the expression of LAG-3. The percentages of cells co-expressing these receptors showed a decrease in the percentage of LAG-3\u2009+\u2009TIM-3\u2009+\u2009PD-1\u2009\u2212\u2009NK and T cells from AML patients in comparison with healthy donors. Remarkably, the survival analysis of AML patients according to the expression of these receptors showed that higher expression of LAG-3 on NK cells and T cells was associated with better survival. In addition, those AML patients showing higher co-expression of LAG-3 and TIM-3 on NK and T cells had better survival (higher than 6\u00a0months) than those with lower co-expression of LAG-3 and TIM-3, therefore supporting that the expansion of NK and T cells with lower expression of these checkpoint receptors reflects a dysfunctional state associated with poor prognosis. This study identifies the expression of LAG-3 and TIM-3 checkpoints on NK and T cells as potential biomarkers of AML prognosis, contributing to define those patients that could benefit from checkpoint blockade\u00a0therapies.<\/jats:p>","DOI":"10.1007\/s00262-025-04169-y","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:26:59Z","timestamp":1759760819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival"],"prefix":"10.1007","volume":"74","author":[{"given":"Isabel","family":"Valhondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Pera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhri","family":"Hassouneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"L\u00f3pez-Sejas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"\u00c1lvarez-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Bergua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Arcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Casas-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"S\u00e1nchez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corona","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Solana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Tarazona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"4169_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.04.020","author":"R Austin","year":"2016","unstructured":"Austin R, Smyth MJ, Lane SW (2016) Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.04.020","journal-title":"Crit Rev Oncol Hematol"},{"key":"4169_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2023.1112059","author":"SZ D\u2019Silva","year":"2023","unstructured":"D\u2019Silva SZ, Singh M, Pinto AS (2023) NK cell defects: implication in acute myeloid leukemia. Front Immunol. https:\/\/doi.org\/10.3389\/FIMMU.2023.1112059","journal-title":"Front Immunol"},{"key":"4169_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082171","author":"I Valhondo","year":"2020","unstructured":"Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Sanchez-Correa B, Guerrero B, Bergua JM, Arcos MJ, Ba\u00f1as H, Casas-Avil\u00e9s I et al (2020) Characterization of the Dnam-1, Tigit and Tactile axis on circulating Nk, Nkt-like and t cell subsets in patients with acute myeloid leukemia. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12082171","journal-title":"Cancers (Basel)"},{"key":"4169_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2011.15","author":"B Sanchez-Correa","year":"2012","unstructured":"Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R (2012) Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol. https:\/\/doi.org\/10.1038\/icb.2011.15","journal-title":"Immunol Cell Biol"},{"key":"4169_CR5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3003","author":"L Tang","year":"2020","unstructured":"Tang L, Wu J, Li CG, Jiang HW, Xu M, Du M, Yin Z, Mei H, Hu Y (2020) Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3003","journal-title":"Clin Cancer Res"},{"key":"4169_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.exger.2007.05.002","volume":"42","author":"E Peralbo","year":"2007","unstructured":"Peralbo E, Alonso C, Solana R (2007) Invariant NKT and NKT-like lymphocytes: two different T cell subsets that are differentially affected by ageing. Exp Gerontol 42:703\u2013708. https:\/\/doi.org\/10.1016\/j.exger.2007.05.002","journal-title":"Exp Gerontol"},{"key":"4169_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142249","author":"Y Abaza","year":"2022","unstructured":"Abaza Y, Zeidan AM (2022) Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells. https:\/\/doi.org\/10.3390\/cells11142249","journal-title":"Cells"},{"key":"4169_CR8","doi-asserted-by":"publisher","first-page":"882531","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M G\u00f3mez-Llobell","year":"2022","unstructured":"G\u00f3mez-Llobell M, Peleteiro Ra\u00edndo A, Climent Medina J, G\u00f3mez Centuri\u00f3n I, Mosquera Orgueira A (2022) Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis. Front Oncol 12:882531","journal-title":"Front Oncol"},{"issue":"5","key":"4169_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00262-019-02336-6","volume":"68","author":"B Sanchez-Correa","year":"2019","unstructured":"Sanchez-Correa B, Lopez-Sejas N, Duran E, Labella F, Alonso C, Solana R, Tarazona R (2019) Modulation of NK Cells with Checkpoint Inhibitors in the Context of Cancer Immunotherapy. Cancer Immunol Immunotherapy 68(5):861\u2013870","journal-title":"Cancer Immunol Immunotherapy"},{"key":"4169_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1720-6","author":"B Sanchez-Correa","year":"2016","unstructured":"Sanchez-Correa B, Campos C, Pera A, Bergua JM, Arcos MJ, Ba\u00f1as H, Casado JG, Morgado S, Duran E, Solana R et al (2016) Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies? Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-015-1720-6","journal-title":"Cancer Immunol Immunother"},{"key":"4169_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.19007","author":"P Apostolova","year":"2023","unstructured":"Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E et al (2023) Phase II trial of hypomethylating agent combined with Nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-immune signature correlates with response. Br J Haematol. https:\/\/doi.org\/10.1111\/BJH.19007","journal-title":"Br J Haematol"},{"key":"4169_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179958","author":"N Sauer","year":"2022","unstructured":"Sauer N, Szlasa W, Jonderko L, O\u015bliz\u0142o M, Kunachowicz D, Kulbacka J, Kar\u0142owicz-Bodalska K (2022) LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23179958","journal-title":"Int J Mol Sci"},{"key":"4169_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/tan.13872","author":"SM Radwan","year":"2020","unstructured":"Radwan SM, Elleboudy NS, Nabih NA, Kamal AM (2020) The immune checkpoints cytotoxic T lymphocyte antigen-4 and lymphocyte activation gene-3 expression is up-regulated in acute myeloid leukemia. HLA. https:\/\/doi.org\/10.1111\/tan.13872","journal-title":"HLA"},{"key":"4169_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.753677","author":"M Rezaei","year":"2021","unstructured":"Rezaei M, Tan J, Zeng C, Li Y, Ganjalikhani-Hakemi M (2021) TIM-3 in leukemia; immune response and beyond. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.753677","journal-title":"Front Oncol"},{"key":"4169_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00049","author":"SJ Judge","year":"2020","unstructured":"Judge SJ, Murphy WJ, Canter RJ (2020) Characterizing the dysfunctional NK cell: assessing the clinical relevance of exhaustion, anergy, and senescence. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2020.00049","journal-title":"Front Cell Infect Microbiol"},{"key":"4169_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112810","author":"M Dey","year":"2019","unstructured":"Dey M, Huff WX, Kwon JH, Henriquez M, Fetcko K (2019) The evolving role of CD8+CD28- immunosenescent T cells in cancer immunology. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20112810","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4169_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41423-019-0344-8","volume":"17","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Shao Q, Peng G (2020) Exhaustion and Senescence: Two Crucial Dysfunctional States of T Cells in the Tumor Microenvironment. Cell Mol Immunol 17(1):27\u201335","journal-title":"Cell Mol Immunol"},{"key":"4169_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S500723","volume":"14","author":"C Chen","year":"2025","unstructured":"Chen C, Qiu K, Chen J, Wang S, Zhang Y, Wang C, Li Y (2025) Increased co-expression of PD-L1 and CTLA-4 predicts poor overall survival in patients with acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. Immunotargets Ther 14:25\u201333. https:\/\/doi.org\/10.2147\/ITT.S500723","journal-title":"Immunotargets Ther"},{"key":"4169_CR19","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M et al (2019) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125:1470\u20131481. https:\/\/doi.org\/10.1002\/cncr.31896","journal-title":"Cancer"},{"key":"4169_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152804","volume":"229","author":"S Pan","year":"2024","unstructured":"Pan S, Cai Q, Wei Y, Tang H, Zhang Y, Zhou W, Deng T, Mo W, Wang S, Wang C et al (2024) Increased co-expression of ICOS and PD-1 predicts poor overall survival in patients with acute myeloid leukemia. Immunobiology 229:152804. https:\/\/doi.org\/10.1016\/j.imbio.2024.152804","journal-title":"Immunobiology"},{"key":"4169_CR21","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.31557\/APJCP.2024.25.5.1777","volume":"25","author":"W El Dosoky","year":"2024","unstructured":"El Dosoky W, Aref S, El Menshawy N, Ramez A, Abou Zaid T, Aref M, Atia D (2024) Prognostic effect of CTLA4\/LAG3 expression by T-cells subsets on acute myeloid leukemia patients. Asian Pac J Cancer Prev 25:1777\u20131785. https:\/\/doi.org\/10.31557\/APJCP.2024.25.5.1777","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"4169_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.20892\/j.issn.2095-3941.2024.0436","volume":"21","author":"X Qiu","year":"2024","unstructured":"Qiu X, Yu Z, Lu X, Jin X, Zhu J, Zhang R (2024) PD-1 and LAG-3 Dual Blockade: Emerging Mechanisms and Potential Therapeutic Prospects in Cancer. Cancer Biol Med 21(11):970\u2013976. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0436","journal-title":"Cancer Biol Med"},{"key":"4169_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, Wang C, Wu J, Wang J, Ma T (2025) TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed 6:27. https:\/\/doi.org\/10.1186\/s43556-025-00267-6","journal-title":"Mol Biomed"},{"key":"4169_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","volume":"79A","author":"M Roederer","year":"2011","unstructured":"Roederer M, Nozzi JL, Nason MC (2011) SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79A:167\u2013174. https:\/\/doi.org\/10.1002\/cyto.a.21015","journal-title":"Cytometry A"},{"key":"4169_CR25","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","volume":"6","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2022","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Meg\u00edas-Vericat JE, Serrano J, Mart\u00ednez-S\u00e1nchez P, Rodr\u00edguez-Arbol\u00ed E, Gil C, Aguiar E, Bergua J, L\u00f3pez-Lorenzo JL, Bernal T et al (2022) Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv 6:1278\u20131295. https:\/\/doi.org\/10.1182\/bloodadvances.2021005335","journal-title":"Blood Adv"},{"key":"4169_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00475","author":"S Khaldoyanidi","year":"2021","unstructured":"Khaldoyanidi S, Nagorsen D, Stein A, Ossenkoppele G, Subklewe M (2021) Immune biology of acute myeloid leukemia: implications for immunotherapy. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.20.00475","journal-title":"J Clin Oncol"},{"key":"4169_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M (2022) Catch Me If You Can: How AML and Its Niche Escape Immunotherapy. Leukemia 36:13\u201322","journal-title":"Leukemia"},{"key":"4169_CR28","doi-asserted-by":"publisher","first-page":"103164","DOI":"10.1016\/j.critrevonc.2020.103164","volume":"157","author":"S Taghiloo","year":"2021","unstructured":"Taghiloo S, Asgarian-Omran H (2021) Immune Evasion Mechanisms in Acute Myeloid Leukemia: A Focus on Immune Checkpoint Pathways. Crit Rev Oncol Hematol 157:103164","journal-title":"Crit Rev Oncol Hematol"},{"key":"4169_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00262-016-1815-8","volume":"65","author":"SL Poh","year":"2016","unstructured":"Poh SL, Linn YC (2016) Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. Cancer Immunol Immunother 65:525\u2013536. https:\/\/doi.org\/10.1007\/s00262-016-1815-8","journal-title":"Cancer Immunol Immunother"},{"key":"4169_CR30","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1182\/blood-2021-151550","volume":"138","author":"D Zhigarev","year":"2021","unstructured":"Zhigarev D, MacFarlane AW, Drenberg CD, Nejati R, Varshavsky A, Campbell KS (2021) NK cells of acute myeloid leukemia patients exhibit exhausted phenotype with impaired functional activity. Blood 138:4466\u20134466. https:\/\/doi.org\/10.1182\/blood-2021-151550","journal-title":"Blood"},{"key":"4169_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01428-2","volume":"22","author":"A Barshidi","year":"2024","unstructured":"Barshidi A, Ardeshiri K, Ebrahimi F, Alian F, Shekarchi AA, Hojjat-Farsangi M, Jadidi-Niaragh F (2024) The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. Cell Commun Signal 22:59. https:\/\/doi.org\/10.1186\/s12964-023-01428-2","journal-title":"Cell Commun Signal"},{"key":"4169_CR32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4142","author":"I Datar","year":"2019","unstructured":"Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mej\u00edas LD et al (2019) Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4142","journal-title":"Clin Cancer Res"},{"key":"4169_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/ijc.32785","volume":"147","author":"L Tu","year":"2020","unstructured":"Tu L, Guan R, Yang H, Zhou Y, Hong W, Ma L, Zhao G, Yu M (2020) Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int J Cancer 147:423\u2013439. https:\/\/doi.org\/10.1002\/ijc.32785","journal-title":"Int J Cancer"},{"key":"4169_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01040","author":"RR Saleh","year":"2019","unstructured":"Saleh RR, Peinado P, Fuentes-Antr\u00e1s J, P\u00e9rez-Segura P, Pandiella A, Amir E, Oca\u00f1a A (2019) Prognostic value of lymphocyte-activation gene 3 (LAG3) in cancer: a meta-analysis. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.01040","journal-title":"Front Oncol"},{"key":"4169_CR35","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.4049\/jimmunol.1401025","volume":"193","author":"J Bae","year":"2014","unstructured":"Bae J, Lee SJ, Park C-G, Lee YS, Chun T (2014) Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling. J Immunol 193:3101\u20133112. https:\/\/doi.org\/10.4049\/jimmunol.1401025","journal-title":"J Immunol"},{"issue":"5","key":"4169_CR36","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME et al (2014) PD-1 Identifies the Patient-Specific CD8+ Tumor-Reactive Repertoire Infiltrating Human Tumors. J Clinical Investigat 124(5):2246\u20132259. https:\/\/doi.org\/10.1172\/JCI73639","journal-title":"J Clinical Investigat"},{"issue":"22","key":"4169_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00262-016-1882-x","volume":"66","author":"R Tarazona","year":"2017","unstructured":"Tarazona R, Sanchez-Correa B, Casas-Avil\u00e9s I, Campos C, Pera A, Morgado S, L\u00f3pez-Sejas N, Hassouneh F, Bergua JM, Arcos MJ et al (2017) Immunosenescence: Limitations of Natural Killer Cell-Based Cancer Immunotherapy. Cancer Immunol Immunotherapy 66(22):233\u2013247","journal-title":"Cancer Immunol Immunotherapy"},{"key":"4169_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/10428194.2020.1839651","volume":"62","author":"S Moerdler","year":"2021","unstructured":"Moerdler S, Ewart M, Friedman DL, Kelly K, Pei Q, Peng M, Zang X, Cole PD (2021) LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma. Leuk Lymphoma 62:606\u2013613. https:\/\/doi.org\/10.1080\/10428194.2020.1839651","journal-title":"Leuk Lymphoma"},{"key":"4169_CR39","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2022-169867","volume":"140","author":"VL Buecklein","year":"2022","unstructured":"Buecklein VL, Warm M, Spiekermann K, Schmidt C, Unterhalt M, Daver N, Subklewe M (2022) Trial in progress: an open-label phase II study of relatlimab with nivolumab in combination with 5-azacytidine for the treatment of patients with relapsed\/refractory and elderly patients with newly diagnosed acute myeloid leukemia (AARON). Blood 140:3227\u20133228. https:\/\/doi.org\/10.1182\/blood-2022-169867","journal-title":"Blood"},{"key":"4169_CR40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-392951","author":"LC Ndhlovu","year":"2012","unstructured":"Ndhlovu LC, Lopez-Verg\u00e8s S, Barbour JD, Brad Jones R, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL (2012) Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. https:\/\/doi.org\/10.1182\/blood-2011-11-392951","journal-title":"Blood"},{"key":"4169_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1889822","author":"J Rakova","year":"2021","unstructured":"Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, Pasulka J, Holubova M, Kovar M, Lysak D et al (2021) TIM-3 Levels Correlate with Enhanced NK Cell Cytotoxicity and Improved Clinical Outcome in AML Patients. Oncoimmunology. https:\/\/doi.org\/10.1080\/2162402X.2021.1889822","journal-title":"Oncoimmunology"},{"key":"4169_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092417","author":"TN Dao","year":"2020","unstructured":"Dao TN, Utturkar S, Lanman NA, Matosevic S (2020) Tim-3 expression is downregulated on human Nk cells in response to cancer targets in synergy with activation. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12092417","journal-title":"Cancers (Basel)"},{"key":"4169_CR43","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S, Niiro H, Yurino A, Miyawaki K, Takenaka K et al (2015) A TIM-3\/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression. Cell Stem Cell 17:341\u2013352. https:\/\/doi.org\/10.1016\/j.stem.2015.07.011","journal-title":"Cell Stem Cell"},{"key":"4169_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.11.014","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, Shima T, Takayanagi SI, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y et al (2010) TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. https:\/\/doi.org\/10.1016\/j.stem.2010.11.014","journal-title":"Cell Stem Cell"},{"key":"4169_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.21147\/j.issn.1000-9604.2017.05.11","volume":"29","author":"J Tan","year":"2017","unstructured":"Tan J, Chen S, Lu Y, Yao D, Xu L, Zhang Y, Yang L, Chen J, Lai J, Yu Z et al (2017) Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia. Chin J Cancer Res 29:463\u2013470. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2017.05.11","journal-title":"Chin J Cancer Res"},{"key":"4169_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100079","author":"L Chocarro","year":"2022","unstructured":"Chocarro L, Blanco E, Arasanz H, Fern\u00e1ndez-Rubio L, Bocanegra A, Echaide M, Garnica M, Ramos P, Fern\u00e1ndez-Hinojal G, Vera R et al (2022) Clinical landscape of LAG-3-targeted therapy. Immuno-Oncology and Technology. https:\/\/doi.org\/10.1016\/j.iotech.2022.100079","journal-title":"Immuno-Oncology and Technology"},{"key":"4169_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04024-0","volume":"74","author":"D-H Xie","year":"2025","unstructured":"Xie D-H, Li S-Q, Sun K, Wang J, Shi Z-Y, Wang Y-Z, Chang Y, Yuan X-Y, Jiang H, Jiang Q et al (2025) The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis. Cancer Immunol Immunother 74:170. https:\/\/doi.org\/10.1007\/s00262-025-04024-0","journal-title":"Cancer Immunol Immunother"},{"key":"4169_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109566","volume":"119","author":"B Bhagwat","year":"2023","unstructured":"Bhagwat B, de Waal Malefyt R, Willingham A (2023) Investigating combination benefit of PD1 and LAG3 co-blockade using an engineered cellular bioassay. Int Immunopharmacol 119:109566. https:\/\/doi.org\/10.1016\/j.intimp.2022.109566","journal-title":"Int Immunopharmacol"},{"key":"4169_CR49","doi-asserted-by":"publisher","first-page":"27359","DOI":"10.18632\/oncotarget.4751","volume":"6","author":"R-Y Huang","year":"2015","unstructured":"Huang R-Y, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K (2015) LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 6:27359\u201327377. https:\/\/doi.org\/10.18632\/oncotarget.4751","journal-title":"Oncotarget"},{"key":"4169_CR50","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1158\/1535-7163.MCT-18-1376","volume":"18","author":"E Burova","year":"2019","unstructured":"Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T, Hong S, Liu M, Allbritton O, Woodruff A et al (2019) Preclinical development of the anti-LAG-3 antibody REGN3767: characterization and activity in combination with the anti-PD-1 antibody cemiplimab in human PD-1xLAG-3 \u2013knockin mice. Mol Cancer Ther 18:2051\u20132062. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1376","journal-title":"Mol Cancer Ther"},{"key":"4169_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60050721","volume":"60","author":"L Mansour","year":"2024","unstructured":"Mansour L, Alqahtani M, Aljuaimlani A, Al-Tamimi J, Al-Harbi N, Alomar S (2024) Association of polymorphisms in PD-1 and LAG-3 genes with acute myeloid leukemia. Medicina (B Aires) 60:721. https:\/\/doi.org\/10.3390\/medicina60050721","journal-title":"Medicina (B Aires)"},{"key":"4169_CR52","doi-asserted-by":"publisher","first-page":"18588","DOI":"10.1002\/cam4.6468","volume":"12","author":"Y Wu","year":"2023","unstructured":"Wu Y, Li M, Meng G, Ma Y, Ye J, Sun T, Ji C (2023) Immune checkpoint-related gene polymorphisms are associated with acute myeloid leukemia. Cancer Med 12:18588\u201318596. https:\/\/doi.org\/10.1002\/cam4.6468","journal-title":"Cancer Med"},{"key":"4169_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2329024","author":"M Alqahtani","year":"2024","unstructured":"Alqahtani M, Aljuaimlani A, Al-Tamimi J, Alomar S, Mansour L (2024) TIM3 and CTLA4 immune checkpoint polymorphisms are associated with acute myeloid leukemia in Saudi Arabia. Hematology. https:\/\/doi.org\/10.1080\/16078454.2024.2329024","journal-title":"Hematology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04169-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04169-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04169-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T17:20:07Z","timestamp":1763054407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04169-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4169"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04169-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of University of Extremadura (No. 73\/2017\u00a0to\u00a0Project SAF2017-87538-R) and Hospital Reina Sof\u00eda (No. 5413 to\u00a0Project PI21\/01125).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}}],"article-number":"325"}}